JP2019528755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528755A5 JP2019528755A5 JP2019516437A JP2019516437A JP2019528755A5 JP 2019528755 A5 JP2019528755 A5 JP 2019528755A5 JP 2019516437 A JP2019516437 A JP 2019516437A JP 2019516437 A JP2019516437 A JP 2019516437A JP 2019528755 A5 JP2019528755 A5 JP 2019528755A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- recombinant poxvirus
- seq
- nucleotides
- contiguous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical class 0.000 claims description 253
- 108020004707 nucleic acids Proteins 0.000 claims description 239
- 102000039446 nucleic acids Human genes 0.000 claims description 239
- 239000002773 nucleotide Substances 0.000 claims description 204
- 125000003729 nucleotide group Chemical group 0.000 claims description 204
- 238000006467 substitution reaction Methods 0.000 claims description 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 108010084313 CD58 Antigens Proteins 0.000 claims description 22
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 22
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 22
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 15
- 102100034256 Mucin-1 Human genes 0.000 claims description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 241000700618 Vaccinia virus Species 0.000 claims description 14
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims description 12
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 12
- 241000700629 Orthopoxvirus Species 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 241000700662 Fowlpox virus Species 0.000 claims description 9
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 6
- 241000700663 Avipoxvirus Species 0.000 claims description 4
- 229940029536 PANVAC Drugs 0.000 claims description 3
- 108010033276 Peptide Fragments Proteins 0.000 claims description 3
- 102000007079 Peptide Fragments Human genes 0.000 claims description 3
- 230000000139 costimulatory effect Effects 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 description 96
- 241000700605 Viruses Species 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000003252 repetitive effect Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662401035P | 2016-09-28 | 2016-09-28 | |
| US62/401,035 | 2016-09-28 | ||
| PCT/EP2017/074693 WO2018060368A2 (en) | 2016-09-28 | 2017-09-28 | Compositions and methods for enhancing the stability of transgenes in poxviruses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528755A JP2019528755A (ja) | 2019-10-17 |
| JP2019528755A5 true JP2019528755A5 (enExample) | 2020-09-24 |
| JP7062003B2 JP7062003B2 (ja) | 2022-05-02 |
Family
ID=60083287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516437A Active JP7062003B2 (ja) | 2016-09-28 | 2017-09-28 | ポックスウイルス内における導入遺伝子の安定性を向上させるための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11052139B2 (enExample) |
| EP (1) | EP3518964A2 (enExample) |
| JP (1) | JP7062003B2 (enExample) |
| KR (1) | KR102605505B1 (enExample) |
| CN (1) | CN110198733B (enExample) |
| AU (1) | AU2017336269B2 (enExample) |
| CA (1) | CA3036799C (enExample) |
| IL (1) | IL265539B (enExample) |
| RU (1) | RU2756534C2 (enExample) |
| WO (1) | WO2018060368A2 (enExample) |
| ZA (1) | ZA201901756B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210046130A1 (en) * | 2018-01-24 | 2021-02-18 | Virogin Biotech Canada Ltd | Recombinant viral vaccines |
| EP3847246A1 (en) * | 2018-09-06 | 2021-07-14 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP3988650A4 (en) * | 2019-06-21 | 2022-09-21 | Osaka University | METHOD OF PRODUCING AN ARTIFICIAL RECOMBINANT RNA VIRUS THAT KEEPS A FOREIGN GENE STABLE |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5122599A (en) | 1986-08-13 | 1992-06-16 | Molecular Diagnostics, Inc. | CDNAS coding for members of the carcinoembryonic antigen family |
| US5766598A (en) | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
| US5744144A (en) | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
| EP0954593A1 (en) | 1996-07-25 | 1999-11-10 | Therion Biologics Corporation | Recombinant pox virus for immunization against tumor-associated antigens |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| EP1456230A2 (en) | 2001-12-04 | 2004-09-15 | Bavarian Nordic A/S | Flavivirus ns1 subunit vaccine |
| GB0212046D0 (en) | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
| GB0304634D0 (en) | 2003-02-28 | 2003-04-02 | Glaxo Group Ltd | Vaccines |
| ES2476990T3 (es) * | 2003-11-12 | 2014-07-15 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sistema para tratar y prevenir cáncer de mama |
| JP5060134B2 (ja) * | 2003-12-12 | 2012-10-31 | ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ | ヒト細胞傷害性Ｔリンパ球のエピトープ及びそのＭＵＣ−１の非ＶＮＴＲ（ｎｏｎ−ｖａｒｉａｂｌｅｎｕｍｂｅｒｏｆｔａｎｄｅｍｒｅｐｅａｔｓｅｑｕｅｎｃｅ）由来のアゴニストエピトープ |
| EP1985305A1 (en) * | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| CA2741724C (en) | 2008-11-27 | 2016-10-04 | Bavarian Nordic A/S | Promoters for recombinant viral expression |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| WO2013103658A1 (en) * | 2012-01-03 | 2013-07-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Native and agonist ctl epitopes of the muc1 tumor antigen |
| US10111946B2 (en) | 2012-06-22 | 2018-10-30 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| MX380483B (es) | 2012-10-28 | 2025-03-12 | Bavarian Nordic As | Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes. |
| AU2014340201B2 (en) | 2013-10-23 | 2019-02-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use |
-
2017
- 2017-09-28 AU AU2017336269A patent/AU2017336269B2/en active Active
- 2017-09-28 CN CN201780059549.XA patent/CN110198733B/zh active Active
- 2017-09-28 EP EP17783784.6A patent/EP3518964A2/en active Pending
- 2017-09-28 CA CA3036799A patent/CA3036799C/en active Active
- 2017-09-28 WO PCT/EP2017/074693 patent/WO2018060368A2/en not_active Ceased
- 2017-09-28 JP JP2019516437A patent/JP7062003B2/ja active Active
- 2017-09-28 KR KR1020197012245A patent/KR102605505B1/ko active Active
- 2017-09-28 US US16/337,086 patent/US11052139B2/en active Active
- 2017-09-28 RU RU2019112725A patent/RU2756534C2/ru active
-
2019
- 2019-03-20 ZA ZA2019/01756A patent/ZA201901756B/en unknown
- 2019-03-21 IL IL265539A patent/IL265539B/en unknown
-
2021
- 2021-07-05 US US17/367,528 patent/US11654189B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2019112725A (ru) | Композиции и способы для повышения стабильности трансгенов в поксвирусах | |
| RU2019119272A (ru) | Вирусная доставка неоантигенов | |
| Schwarz et al. | Efficient homologous prime‐boost strategies for T cell vaccination based on virus‐like particles | |
| CA2741724C (en) | Promoters for recombinant viral expression | |
| KR101196178B1 (ko) | Ｈｉｖ 조절/부속 단백질의 융합 단백질 | |
| JP2021522784A5 (enExample) | ||
| JP2018521651A5 (enExample) | ||
| WO2012172277A4 (en) | Simian adenovirus and hybrid adenoviral vectors | |
| Alharbi | Poxviral promoters for improving the immunogenicity of MVA delivered vaccines | |
| Baur et al. | Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses | |
| CA2408328A1 (en) | Immunogenic polypeptides encoded by mage minigenes and uses thereof | |
| JP2014516536A5 (enExample) | ||
| JP2019500907A5 (enExample) | ||
| JP2019535311A5 (enExample) | ||
| JP2024535145A5 (enExample) | ||
| JP2019537446A5 (enExample) | ||
| JP2018521651A (ja) | ポックスウイルスにおける発現を増強するためのプロモーター | |
| JP2024105526A5 (enExample) | ||
| CA2459754A1 (en) | Vaccinia virus mva-e3l-knock-out-mutants and use thereof | |
| US20090053256A1 (en) | Poxvirus Methods And Compositions | |
| CN102086453B (zh) | 以粘蛋白1和生存素为靶点的肿瘤dna疫苗及病毒载体疫苗 | |
| JP2016082979A5 (enExample) | ||
| CN102732543B (zh) | 以粘蛋白1和生存素为靶点的肿瘤基因工程疫苗 | |
| WO2025231384A1 (en) | Human papilloma virus immunogen compositions and uses thereof | |
| CN104491852B (zh) | 以粘蛋白1和生存素为靶点的肿瘤dna疫苗及病毒载体疫苗 |